HIV/TB Research Frontiers Meeting in conjunction with the Conference on Retroviruses and Opportunistic Infections (CROI 2014),

Latency in TB and HIV: Opportunities, challenges and the way forward

Monday March 3, 2014, 11:30-13:30

Sheraton Boston Hotel, Back Bay Ballroom B, 39 Dalton Street, Boston, MA 02199, USA

 

Organized by the World Health Organization

 WHO is organizing the 8th CROI-affiliated HIV/TB Research Frontiers meeting which will be held on Monday 3rd March 2014, 11:30-13:30 at the Sheraton Hotel, Boston, MA, USA. A third of all people living with HIV worldwide are latently infected with Mycobacterium tuberculosis (MTB), making them 30 times more likely to develop active TB disease than people who are HIV negative. Individuals who contain the infection of MTB at the initial lesion may still harbour viable bacilli that can raise the risk of developing active disease. Similarly, the latent reservoir for HIV-1 in resting memory CD4 T cells is the major barrier to curing HIV infection. The meeting will discuss and highlight ongoing and emerging research and programmatic opportunities to synergise the research response with particular focus on latency of TB and HIV. Challenges will be explored and research questions and hypotheses will be developed. The meeting is intended for HIV and TB researchers, implementers and public health policy makers. Attendance of the meeting will be by invitation only and on a first come first serve basis. If you are interested in participating please send your interest to tbhiv@who.int at your earliest convenience but no later than close of business on 24th February 2014. Please see below for the provisional agenda. A light lunch will be served during the meeting.

Provisional Agenda

Convener: Haileyesus Getahun, Global TB Programme, WHO

Chair: Ambassador Eric Goosby, Chair of the Global TB/HIV Working Group

11:30-11:35: Introduction and implications of the meeting Ambassador Eric Goosby, University of California, San Francisco (UCSF)and Chair of the Global TB/HIV Working Group

11:35-11:55: Latency in HIV: Opportunities, challenges and the way forward Joseph McCune, UCSF

11:55-12:00: Commentary (Discussant to be advised)

12:00-12:30: Discussion

 12:30-12:50: Latency in TB: Opportunities, challenges and the way forward Sarah Fortune, Harvard School of Public Health

12:50-12:55: Commentary (Discussant to be advised)

12:55-13:25: Discussion

13:25-13:30: General conclusion and next steps

The key issues covered at previous meetings are summarized below:

  • TB prevention among people living with HIV, HIV treatment in TB patients, TB-IRIS, smear-negative TB and HIV, XDR-TB and HIV (CROI 2007)
  • Isoniazid preventive therapy and enhanced TB case finding among people living with HIV  (CROI 2008)
  • The magnitude and burden of TB, including drug resistant strains, in HIV prevalent settings (CROI 2009)
  • Impact of isoniazid preventive therapy in improving survival among people living with HIV (CROI 2010).
  • Xpert MTB/RIF to diagnose drug susceptible and drug resistant TB among people living with HIV and controversies of the mouse model in TB drug development with implications for people living with HIV. (CROI2011)
  • Measurement and reduction of TB transmission in high HIV burden settings (CROI2012)
  • TB prevention among people living with HIV and drug-drug interactions between new TB drugs and ART.(CROI 2013)

For the reports of research meetings from previous years please see the following link.

Categories: Acara, Informasi

Leave a Reply


 

Find Us on Youtube



Sponsors

  • Global Fund Fighting AIDS, Tuberculosis, Malaria
  • WHO Stop TB Departement
  • From The American People
  • KNCV Indonesia